OverviewSuggest Edit

Veracyte is a genomic diagnostics company. It is engaged in the development of molecular tests that leverage innovations in genomic technology and machine learning to enable diagnostic, prognostic, and treatment decisions in diseases such as thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis.

TypePublic
Founded2008
HQSouth San Francisco, CA, US
Websiteveracyte.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)354(+32%)
Job Openings13
Revenue (FY, 2020)$117.5 M(-2%)
Share Price (Apr 2021)$49.5
Cybersecurity ratingBMore

Key People/Management at Veracyte

Bonnie H. Anderson

Bonnie H. Anderson

Chairman of the Board and Chief Executive Officer
Keith Kennedy

Keith Kennedy

Chief Operating Officer and Chief Financial Officer
Giulia C. Kennedy

Giulia C. Kennedy

Chief Scientific Officer and Chief Medical Officer
James Erlinger

James Erlinger

Executive Vice President, General Counsel and Secretary
John W. Hanna

John W. Hanna

General Manager, Endocrinology, Breast Cancer and Lymphoma
Morten Frost

Morten Frost

General Manager, Pulmonology
Show more

Veracyte Office Locations

Veracyte has offices in South San Francisco and Austin
South San Francisco, CA, US (HQ)
6000 Shoreline Ct #300
Austin, TX, US
12357 Riata Trace Pkwy Building 5, Suite 100
Show all (2)

Veracyte Financials and Metrics

Veracyte Revenue

Veracyte's revenue was reported to be $117.48 m in FY, 2020
USD

Revenue (FY, 2020)

117.5m

Net income (FY, 2020)

(34.9m)

EBIT (FY, 2020)

(35.4m)

Market capitalization (23-Apr-2021)

3.3b

Closing stock price (23-Apr-2021)

49.5

Cash (31-Dec-2020)

349.4m

EV

3.0b
Veracyte's current market capitalization is $3.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

72.0m92.0m120.4m117.5m

Revenue growth, %

28%31%

Cost of goods sold

28.2m33.1m36.5m

Gross profit

43.8m58.9m83.8m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

20.0m22.8m23.5m29.5m30.1m31.0m31.1m20.7m31.1m

Cost of goods sold

7.9m8.2m8.3m8.5m8.8m9.1m12.2m7.7m10.4m

Gross profit

12.2m14.5m15.2m21.0m21.4m21.9m18.9m13.0m20.8m

Gross profit Margin, %

61%64%65%71%71%71%61%63%67%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

33.9m78.0m159.3m349.4m

Accounts Receivable

12.7m13.2m19.3m18.5m

Prepaid Expenses

2.0m2.4m2.2m3.2m

Inventories

5.3m3.4m6.8m4.7m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

27.2m23.8m77.8m67.8m192.6m195.7m153.1m147.5m345.1m

Accounts Receivable

13.2m13.0m12.3m16.6m19.6m23.6m19.1m15.3m17.6m

Prepaid Expenses

2.1m1.8m1.8m2.4m2.6m2.2m3.0m2.9m3.2m

Inventories

4.6m3.0m3.5m3.8m5.1m6.6m6.1m7.0m4.5m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(31.0m)(23.0m)(12.6m)(34.9m)

Depreciation and Amortization

3.8m3.9m4.1m7.9m

Inventories

(1.8m)1.9m(3.4m)1.1m

Accounts Payable

1.7m(1.6m)(141.0k)711.0k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(9.2m)(15.4m)(19.9m)(1.9m)(4.4m)(5.1m)(11.7m)(22.7m)(26.9m)

Depreciation and Amortization

980.0k2.0m3.0m945.0k1.9m2.8m2.0m3.9m5.9m

Inventories

767.0k2.3m1.9m(366.0k)(1.7m)(3.2m)(376.0k)(1.3m)1.3m

Accounts Payable

(510.0k)(1.9m)(2.6m)1.7m1.7m2.5m5.5m122.0k(534.0k)
USDFY, 2017

Revenue/Employee

292.5k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.1 x
Show all financial metrics

Veracyte Operating Metrics

FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020

Genomic Classifiers Reported

26.03 k6.86 k7.69 k8.01 k31.71 k9.16 k9.66 k9.94 k39.61 k10.56 k5.38 k

Genomic Tests Offered

335

Completed Clinical Studies to Date

303845

Facilities

222
Show all operating metrics

Veracyte Acquisitions / Subsidiaries

Company NameDateDeal Size
Allegro DiagnosticsSeptember 04, 2014$21 m
Veracyte International Corp.

Veracyte Revenue Breakdown

Embed Graph

Veracyte revenue breakdown by business segment: 89.2% from Testing Revenue, 6.7% from Biopharmaceutical Revenue and 4.1% from Other

Veracyte Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Veracyte Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Veracyte Online and Social Media Presence

Embed Graph

Veracyte Company Culture

  • CEO Rating

    A+

    100/100

Learn more on Comparably

Veracyte News and Updates

Veracyte Appoints Muna Bhanji to Its Board of Directors

Veracyte announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately

Veracyte Completes Acquisition of Decipher Biosciences

Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into 7 of the 10 most common cancers in the United States, while accelerating revenue growth

Veracyte to Present at Btig Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, a…

Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2020 after the close of market on Wednesday, February 17. Company management will host a conference call and webcast to discuss its financial results and provide a gener…

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 8,547,297 shares of common stock, including 1,114,864 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $74.00 per share. The net proceeds to Veracy…

Veracyte to Present at Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to participate in two upcoming virtual investor conferences
Show more

Veracyte Blogs

Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO

Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO Content Import Thu, 04/29/2021 - 08:31 Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO Apr 29, 20…

Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 27, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier (GSC), a novel genomic test, in helping to improve lung cancer

Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 20, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the first quarter of 2021 after the close of market on Monday, May 10 . Company management will host a conference call and webcast to

Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference

- New data support role of Percepta Genomic Atlas in genomic profiling for lung cancer patients – - Study suggests Envisia classifier can be successfully enabled on nCounter Analysis System - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2021-- Veracyte, Inc .

Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results

Keith Kennedy will retire following Q1 earnings release and 10-Q; Jane Alley appointed as acting CFO; Veracyte to conduct CFO search SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 15, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced that Keith Kennedy , chief financial officer and chief

Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test

Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test Content Import Wed, 04/14/2021 - 08:31 Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test …
Show more

Veracyte Frequently Asked Questions

  • When was Veracyte founded?

    Veracyte was founded in 2008.

  • Who are Veracyte key executives?

    Veracyte's key executives are Bonnie H. Anderson, Keith Kennedy and Giulia C. Kennedy.

  • How many employees does Veracyte have?

    Veracyte has 354 employees.

  • What is Veracyte revenue?

    Latest Veracyte annual revenue is $117.5 m.

  • What is Veracyte revenue per employee?

    Latest Veracyte revenue per employee is $331.9 k.

  • Who are Veracyte competitors?

    Competitors of Veracyte include Caris Life Sciences, Castle Biosciences and Biodesix.

  • Where is Veracyte headquarters?

    Veracyte headquarters is located at 6000 Shoreline Ct #300, South San Francisco.

  • Where are Veracyte offices?

    Veracyte has offices in South San Francisco and Austin.

  • How many offices does Veracyte have?

    Veracyte has 2 offices.